---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035686"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:39:43.987835+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity: Two stenoparib patients exceed 14 months; $18.5M cash; lab services revenue

## Summary
- Two advanced ovarian cancer patients on stenoparib Phase 2 trial beyond 14 months, a notable duration given heavy pretreatment.
- Cash balance of $18.5M as of Sept 30, 2024, sufficient to initiate registrational trial toward FDA approval.
- Allarity Medical Lab signs external service agreements for DRP and gene expression analysis with multiple biotech firms.
- Revenue from lab services reduces overall lab cost base and advances DRP platform in oncology field.

## SEC filing metadata
- accession: 0001437749-24-035686
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/0001437749-24-035686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774924035686/allr20241118_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035686
- JSON: https://secwatch.observer/filing/0001437749-24-035686.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035686.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.